Puma Biotechnology Reports Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Puma Biotech (PBYI) Tops Q2 EPS by 65c, Revenues Miss
August 6, 2020 5:53 PM EDTPuma Biotech (NASDAQ: PBYI) reported Q2 EPS of $0.35, $0.65 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $48.8 million versus the consensus estimate of $58.21 million.
We are pleased to announce that despite the challenges presented by the COVID-19 situation as well as a significant inventory draw down by specialty pharmacies in the quarter, we were able to... More



